Rodríguez-González M, Espinosa-Rosales F

Language: Spanish
References: 6
Page: 349-354
PDF size: 583.09 Kb.

Text Extraction

No abstract.

REFERENCES

1. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13.

2. Buttgereit F, Da Silva JA, Boers M, Burmester GR, Cutolo M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 61, 718-722.

3. Ramamoorthy S, Cidlowski JA. Rheum Dis Clin N Am 42 (2016) 15–31.

4. Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol. 2013 Nov 5;380(1-2):32-40.

5. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: The Pharmacological Basis of Therapeutics, 11th ed, Brunton LL, Lazo JS, Parker KL (Eds), McGraw Hill, NY. p.1587.

6. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833.